Deutetrabenazine Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 6 mg, 9 mg, 12 mg, 15 mg, 18 mg, 21 mg, 24 mg

Reference Brands: Austedo (USA/EU)

Category: Neurology

Deutetrabenazine is a CNS-active medication used to treat involuntary movements (chorea) in Huntington’s disease and tardive dyskinesia. It works by modulating dopamine levels in the brain, helping to reduce abnormal, involuntary movements. Austedo is available as oral tablets in multiple strengths (6 mg–24 mg) and is typically taken twice daily, with dosing adjusted according to patient response and tolerability.

Product Description:

Deutetrabenazine inhibits vesicular monoamine transporter 2, depleting dopamine from presynaptic vesicles and reducing the excess dopaminergic signalling that produces involuntary movement. Its distinguishing feature is chemical: six hydrogen atoms are replaced by deuterium, which strengthens the carbon-hydrogen bonds that metabolising enzymes must break. Clearance slows, plasma levels are steadier, and the same effect can be achieved at roughly half the dose of tetrabenazine with less peak-related sedation and depression.

It is indicated for chorea associated with Huntington's disease and for tardive dyskinesia, taken twice daily with food and titrated slowly. The class carries a boxed warning for depression and suicidality in Huntington's patients, who are already at elevated risk, and treatment requires active monitoring of mood. Parkinsonism, somnolence, akathisia and QT prolongation occur; dose limits apply in CYP2D6 poor metabolisers and when strong inhibitors are co-prescribed.

Sourcing notes. Originator product, on patent, with a deuterated structure that is separately protected. Seven tablet strengths exist to support titration, so a meaningful quotation must cover the range rather than a single strength. This is a neurological product and is placed here in error.